Cresco Labs (CRLBF) Capital Leases (2023 - 2026)

Cresco Labs (CRLBF) reported Capital Leases of $17.6 million for Q1 2026, down 3.91% quarter-over-quarter from $18.3 million in Q4 2025.

Cresco Labs (CRLBF) Capital Leases (2023 - 2026) Analysis & Trends

Cresco Labs has reported Capital Leases for 3 years, with the latest figure at $17.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Capital Leases changed N/A year-over-year to $17.6 million; the trailing twelve-month figure through Mar 2026 stood at $17.6 million (changed N/A YoY), and the FY2025 full-year result was $18.3 million, changed N/A from the prior year.
  • Capital Leases for Q1 2026 stood at $17.6 million, down from $18.3 million in the prior quarter.
  • The five-year high for Capital Leases was $22.4 million in Q4 2023, with the low at $17.6 million in Q1 2026.
  • Historically, Capital Leases has averaged $19.4 million across 3 years, with a median of $18.3 million in 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Cresco Labs - - 75.45 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 17.56 Mn
Dec 31, 2025 18.27 Mn
Dec 31, 2023 22.38 Mn